IP Library Granted Patent US 8,431,139
Granted Patent B2
US 8,431,139 · App. 11/434,203 · Granted Apr 30, 2013

Nucleic acids and proteins from

Inventors: John Telford (Monteriggioni, IT); Vega Masignani (Siena, IT); Maria Scarselli (Siena, IT); Guido Grandi (Segrate, IT); Herve Tettelin (Rockville, MD); Claire Fraser (Clarksville, MD)
Assignees: Novartis Vaccines and Diagnostics, Inc.; J. Craig Venter Institute
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,431,139
App. No.
11/434,203
Granted
Apr 30, 2013
Kind
B2
Abstract

The invention provides proteins from group B streptococcus ( Streptococcus agalactiae ) and group A streptococcus ( Streptococcus pyogenes ), including amino acid sequences and the corresponding nucleotide sequences. Data are given to show that the proteins are useful antigens for vaccines, immunogenic compositions, and/or diagnostics. The proteins are also targets for antibiotics.

Claims (33)

1. An isolated or recombinant S. agalactiae polypeptide in substantially pure form comprising twelve or more consecutive amino acids from the amino acid sequence SEQ ID NO:3744.

2. The isolated or recombinant S. agalactiae polypeptide of claim 1 wherein the polypeptide comprises 20 consecutive amino acids from the amino acid sequence SEQ ID NO:3744.

3. The isolated or recombinant S. agalactiae polypeptide of claim 1 wherein the polypeptide comprises 50 consecutive amino acids from the amino acid sequence SEQ ID NO:3744.

4. The isolated or recombinant S. agalactiae polypeptide of claim 1 wherein the polypeptide comprises 70 consecutive amino acids from the amino acid sequence SEQ ID NO:3744.

5. The isolated or recombinant S. agalactiae polypeptide of claim 1 wherein the polypeptide comprises 100 consecutive amino acids from the amino acid sequence SEQ ID NO:3744.

6. The isolated or recombinant S. agalactiae polypeptide of any of claim 1 , 2 , 3 , 4 , or 5 , wherein the polypeptide is a recombinant polypeptide.

7. The isolated or recombinant S. agalactiae polypeptide of any of claim 1 , 2 , 3 , 4 , or 5 , wherein the polypeptide is a purified polypeptide.

8. A composition comprising:

an isolated or recombinant S. agalactiae polypeptide in substantially pure form comprising twelve or more consecutive amino acids from the amino acid sequence SEQ ID NO:3744; and

an adjuvant.

9. The composition of claim 8 wherein the polypeptide comprises 20 consecutive amino acids from the amino acid sequence SEQ ID NO:3744.

10. The composition of claim 8 wherein the polypeptide comprises 50 consecutive amino acids from the amino acid sequence SEQ ID NO:3744.

11. The composition of claim 8 wherein the polypeptide comprises 70 consecutive amino acids from the amino acid sequence SEQ ID NO:3744.

12. The composition of claim 8 wherein the polypeptide comprises 100 consecutive amino acids from the amino acid sequence SEQ ID NO:3744.

13. The composition of claim 8 wherein the polypeptide is a recombinant polypeptide.

14. The composition of claim 8 , wherein the adjuvant comprises an aluminium salt.

15. The composition of claim 8 wherein the polypeptide is a purified polypeptide.

16. The composition of claim 14 wherein the aluminium salt is alum.

17. The composition of claim 16 wherein the polypeptide is a purified polypeptide.

18. The composition of claim 16 wherein the polypeptide is a recombinant polypeptide.

19. The composition of claim 14 wherein the polypeptide is a recombinant polypeptide.

20. The composition of claim 14 wherein the polypeptide is a purified polypeptide.

21. The composition of claim 8 , wherein the adjuvant comprises squalene, polyoxyethylene sorbitan monooleate, and sorbitan trioleate.

22. The composition of claim 21 wherein the polypeptide is a purified polypeptide.

23. The composition of claim 21 wherein the polypeptide is a recombinant polypeptide.

24. An isolated or recombinant S. agalactiae polypeptide in substantially pure form which comprises the amino acid sequence SEQ ID NO:3744.

25. The isolated or recombinant S. agalactiae polypeptide of claim 24 , wherein the polypeptide is a purified polypeptide.

26. The isolated or recombinant S. agalactiae polypeptide of claim 24 , wherein the polypeptide is a recombinant polypeptide.

27. A composition comprising:

an isolated or recombinant S. agalactiae polypeptide comprising the amino acid sequence SEQ ID NO:3744; and

an adjuvant.

28. The composition of claim 27 , wherein the polypeptide is a purified polypeptide.

29. The composition of claim 27 , wherein the polypeptide is a recombinant polypeptide.

Assignments (7)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 20, 2016
From: NOVARTIS VACCINES AND DIAGNOSTICS SRL
To: GLAXOSMITHKLINE BIOLOGICALS SA
Reel/Frame 040077/0574 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 20, 2009
From: NOVARTIS VACCINES AND DIAGNOSTICS SRL
To: NOVARTIS VACCINES AND DIAGNOSTICS, INC.
Reel/Frame 023548/0991 →
CHANGE OF NAME Recorded Nov 20, 2009
From: CHIRON SRL
To: NOVARTIS VACCINES AND DIAGNOSTICS SRL
Reel/Frame 023550/0436 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 15, 2009
From: SCARSELLI, MARIA
To: NOVARTIS VACCINES AND DIAGNOSTICS, INC.
Reel/Frame 022956/0119 →
MERGER Recorded Jul 8, 2009
From: CHIRON CORPORATION
To: NOVARTIS VACCINES AND DIAGNOSTICS, INC.
Reel/Frame 022930/0956 →
MERGER Recorded Jun 19, 2009
From: THE INSTITUTE FOR GENOMIC RESEARCH, INC.
To: J. CRAIG VENTER INSTITUTE
Reel/Frame 022850/0313 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 16, 2006
From: CHIRON CORPORATION
To: NOVARTIS VACCINES AND DIAGNOSTICS, INC.
Reel/Frame 017901/0828 →
Priority Claims (3)
GB 0026333.5 · Oct 27, 2000 · national
GB 0028727.6 · Nov 24, 2000 · national
GB 0105640.7 · Mar 7, 2001 · national
Continuity (2)
Division 10415182
Related Publication 20060210582A1 · Sep 21, 2006